Blog

Department of Oncology RetreatAssay Genie was honoured to sponsor and participate in the inaugural 2025 Department of Oncology Retreat, hosted by the University of Lausanne and Lausanne University Hospital (CHUV) at the beautiful and historic Château d’Oron, alongside our valued Swiss partner, Chemie Brunschwig.With over 180 attendees, including principal investigators, lab managers, students, and administrative staff, the retreat celebrated more than 40 years of the Department’s international leadership in cancer and biomedical research.As a proud premium sponsor, Assay Genie reaffirmed its commitment to supporting the oncology community and advancing groundbreaking research i …

Cure CLCN4 2025Assay Genie was honored to attend and present at the 2025 Cure CLCN4 Scientific Conference, held on May 19–20 at Friends House in London and online. This annual event, now in its fourth year, brought together researchers, clinicians, industry leaders, and families to advance understanding and treatment of CLCN4-related neurodevelopmental disorders.As a proud platinum sponsor, Assay Genie reaffirmed its long-standing support for the Cure CLCN4 community. Since 2022, we have partnered with Cure CLCN4 to provide high-quality reagents and scientific insights that empower researchers worldwide. Our sponsorship underscores our dedication to accelerating research in rar …

Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like chronic lymphocytic leukemia (CLL).What is the mechanism of action for Alemtuzumab?Alemtuzumab binds to CD52 on lymphocytes, leading to their depletion via immune-mediated cytotoxicity, resetting the immune system in diseases like MS.What are the clinical applications of Alemtuzumab?Alemtuzumab is FDA-approved for relapsing-remitting multiple sclerosis (RRMS) and is used off-label for various hematologic conditions.What are Alemtuzumab’s common side effects?Side effects include infusion-related …

Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while enhancing immune response.What are the clinical applications of Enavatuzumab?It is under investigation for treating solid tumors and hematologic malignancies due to its dual action of direct tumor cell targeting and immune system modulation.Is Enavatuzumab safe?Emerging studies indicate a manageable safety profile, though further trials are crucial …

Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune destruction.What role does Praluzatamab play in targeting CD47?It blocks CD47–SIRPα signaling, promoting phagocytosis of tumor cells and enhancing antitumor immune responses.Is Praluzatamab safe?Initial studies reported tolerable safety profiles, but further trials were needed to fully assess its risks and hematologic side effects.What are the clinical applications of Praluzatamab?Praluzatamab has been investigated for treating myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and soli …

What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cell lymphomas like DLBCL.What is the mechanism of action for Polatuzumab?It delivers a cytotoxic payload directly to B cells by binding to CD79b, leading to selective cell death with reduced off-target effects.What are the clinical applications of Polatuzumab?Polatuzumab is used in combination therapies for relapsed/refractory DLBCL and is being explored for front-line treatment.Is Polatuzumab safe?It has a manageable safety profile, with common side effects including neutropenia, peripheral neuro …

Assay Genie attended AACR 2025 in ChicagoSean, Shane and David had a great few days in Chicago discussing research with scientists from across the globe at the Assay Genie booth. "It's great to see the progress being made in cancer discoveries each year we attend the AACR and meeting the researchers that are so enthusiastic about the role they play in helping cure cancer" - Seán Mac Fhearraigh PhD (Assay Genie Co-Founder).Next year Assay Genie will be in San Diego attending the 2026 edition to continue their goal of making scientists smile and hopefully playing a role in progessing our knowledge of cancer. …

IgA Testing: Complete Diagnostic Guide + Interpretation Methods | Expert ProtocolsThe IgA test, also known as immunoglobulin A test, is a diagnostic tool used to measure the levels of IgA antibodies in the blood. Immunoglobulin A (IgA) is a type of antibody that plays a crucial role in the immune system's defense against infections. This test helps in diagnosing certain medical conditions related to the immune system, such as autoimmune diseases and allergies. In this comprehensive guide, we will delve deeper into the importance of the IgA test, its procedure, interpretation of results, factors affecting IgA levels, and clinical significance.Importance of IgA TestImmunoglo …

What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.What is the mechanism of action for Milatuzumab?Milatuzumab binds CD74, interrupting survival pathways and triggering antibody-dependent cell-mediated cytotoxicity (ADCC).Is Milatuzumab safe?Milatuzumab has shown manageable safety in early trials, though further studies are needed to fully define its toxicity profile.What diseases is Milatuzumab being studied for?Milatuzumab has been investigated in hematological malignancies like multiple myeloma and chronic lymphocytic leukemia, and autoimmune …

What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer cells.What is the mechanism of action for Ozuriftamab?It blocks the CD47 “don’t eat me” signal, enabling macrophages to recognize and eliminate malignant cells more effectively.What are the clinical applications of Ozuriftamab?Ozuriftamab has been studied primarily in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), showing potential in combination therapies.Is Ozuriftamab safe?Initial studies revealed a manageable safety profile, although treatment-emergent cytopenias and infusi …

Quick Facts About ErenumabWhat is Erenumab?Erenumab is a fully human monoclonal antibody designed to prevent migraines by targeting the calcitonin gene-related peptide (CGRP) receptor. ​How does Erenumab work?It binds selectively to the CGRP receptor, inhibiting its function and thereby reducing migraine frequency. ​What are the clinical applications of Erenumab?Erenumab is primarily used for the preventive treatment of migraines in adults. ​1.) Understanding ErenumabErenumab represents a significant advancement in migraine therapy as the first FDA-approved treatment specifically designed to prevent migraines by inhibiting the calcitonin gene-related peptide (CGRP) receptor. De …

Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammatory autoimmune conditions.What is the mechanism of action for Guselkumab?It inhibits IL-23 signaling by binding to the p19 subunit, disrupting downstream inflammatory pathways involved in diseases like psoriasis and psoriatic arthritis.Is Guselkumab safe?Clinical trials have shown Guselkumab to have a favorable safety profile, with most side effects being mild to moderate, such as upper respiratory infections and injection-site reactions.What conditions does Guselkumab treat?Guselkumab is FDA-appr …

Quick Facts About NarsoplimabWhat is Narsoplimab?Narsoplimab is a human monoclonal antibody that targets MASP-2, a key enzyme in the lectin pathway of the complement system.What is the mechanism of action for Narsoplimab?Narsoplimab inhibits MASP-2, blocking the activation of the lectin complement pathway and reducing inflammatory damage in immune-mediated diseases.What are the clinical applications of Narsoplimab?It has been studied in IgA nephropathy, HSCT-TMA, and other inflammatory conditions, with emerging evidence in COVID-19-related trials.Is Narsoplimab FDA-approved?Narsoplimab has received Breakthrough Therapy designation, but full FDA approval is pending further data …

Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epithelial cancers.What is the mechanism of action for Farletuzumab?It binds to FRα on tumor cells and mediates cytotoxic effects via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and internalization.What are the clinical applications of Farletuzumab?It has been explored in clinical trials for epithelial ovarian cancer, particularly in combination with agents like carboplatin, paclitaxel, or eribulin.Is Farletuzumab used with Ecteribulin?Yes. Farletuzumab …

Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of action for Ulviprubart?Ulviprubart targets the complement system, reducing excessive immune activation and preventing tissue damage.What are the clinical applications of Ulviprubart?Research is evaluating Ulviprubart’s potential in treating autoimmune diseases such as lupus, rheumatoid arthritis, and atypical hemolytic uremic syndrome.1.) Understanding UlviprubartUlviprubart represents a significant advancement in immunotherapy, particularly for autoimmune diseases where excessive compleme …

Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukemia (CLL) and follicular lymphoma.What is the mechanism of action for Obinutuzumab?Obinutuzumab works by binding to CD20 on B-cells, inducing direct cell death and enhancing antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis.What are the clinical applications of Obinutuzumab?It is approved for CLL and follicular lymphoma, often in combination with other therapies such as venetoclax or bendamustine.1.) Understanding ObinutuzumabObinutuzumab, a next-generation glycoengineered monoclon …

Quick Facts About AbituzumabWhat is Abituzumab?Abituzumab is a monoclonal antibody that targets αv-integrins, playing a role in cancer treatment and fibrotic diseases.What is the mechanism of action for Abituzumab?It inhibits αv-integrins to prevent tumor cell adhesion, migration, and survival, making it a potential therapy for colorectal and prostate cancer.What are the clinical applications of Abituzumab?It has been investigated for metastatic colorectal cancer (CRC), prostate cancer, systemic sclerosis, and fibrotic diseases like scleroderma.1.) Understanding AbituzumabInitially developed by Merck Serono, Abituzumab has undergone extensive preclinical and clinical evaluation …

Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat me" signal.What is the mechanism of action for Tomaralimab?Tomaralimab inhibits CD47, a protein that allows cancer cells to evade macrophage-mediated phagocytosis. By blocking CD47, it promotes immune clearance of tumors.What are the clinical applications of Tomaralimab?It has been investigated in hematologic malignancies and solid tumors, with ongoing research into its potential combination therapies.1.) Understanding TomaralimabTomaralimab represents a significant advancement in immuno-oncolog …

Quick Facts About ApamistamabWhat is Apamistamab?Apamistamab is a monoclonal antibody that targets the CD45 antigen on hematopoietic cells.How does Apamistamab work?When labeled with the radioactive isotope Iodine-131, Apamistamab delivers targeted radiation to CD45-expressing cells, aiding in the eradication of malignant cells.What are the clinical applications of Apamistamab?Apamistamab is primarily used in conditioning regimens before hematopoietic cell transplantation for patients with relapsed or refractory acute myeloid leukemia (AML).1.) Understanding ApamistamabApamistamab, also known as Iomab-B when conjugated with Iodine-131, is an innovative therapeutic agent designe …

Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate immune response in lupus.What is the mechanism of action of Litifilimab?Litifilimab inhibits BDCA2, reducing inflammatory cytokine production and modulating the immune system, potentially benefiting lupus patients.What are the clinical applications of Litifilimab?Litifilimab is being investigated for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), with Phase 3 trials ongoing.1.) Understanding LitifilimabDeveloped by Biogen, Litifilimab has shown promising results in e …

Quick Facts About BegelomabWhat is Begelomab?Begelomab is a monoclonal antibody that targets CD26, a key molecule involved in immune regulation. It has been studied for its potential applications in treating T-cell mediated disorders, including graft-versus-host disease (GVHD).How Does Begelomab Work?Begelomab binds to CD26, modulating immune responses by affecting T-cell activation and signaling pathways. This makes it a promising candidate for managing autoimmune conditions and post-transplant complications.What Are the Clinical Applications of Begelomab?Begelomab has been explored in clinical settings for treating steroid-refractory acute GVHD, a severe complication followin …

Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).How does Durvalumab work?Durvalumab blocks PD-L1, restoring the immune system's ability to recognize and attack cancer cells.What are the clinical applications of Durvalumab?It is FDA-approved for treating NSCLC, SCLC, and biliary tract cancer and is being explored in combination therapies.What are the side effects of Durvalumab?Common side effects include fatigue, cough, and immune-related reactions such as pneumonitis and colitis.1.) Understanding Durva …

Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eliminate cancer cells.How Does Galegenimab Work?By targeting CD47, Galegenimab prevents cancer cells from evading macrophage-mediated phagocytosis, a critical mechanism in immune response.What Are the Clinical Applications of Galegenimab?Galegenimab is being investigated for its potential in treating hematologic malignancies and solid tumors, particularly in combination with other immunotherapies.1.) Understanding GalegenimabGalegenimab represents a significant advancement in immuno-oncology by ta …

Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary HLH, a life-threatening hyperinflammatory condition.What is the mechanism of action of Emapalumab?Emapalumab binds to and neutralizes IFN-γ, reducing excessive immune activation in HLH patients. By targeting this key cytokine, it helps control inflammation and prevent tissue damage.What are the clinical applications of Emapalumab?Emapalumab is primarily used to treat pediatric and adult patients with primary HLH who are unresponsive to conventional treatments. It is also being explored for seco …